This site is intended for health professionals only

At the heart of general practice since 1960

GP scandalised by £30-an-hour OOH shift

The cardiovascular safety of cox-2 inhibitors remains unproven, warns the US Food and Drug Administration

The agency claimed existing trials were inadequately powered to detect excess cardiovascular events and said it would be reviewing the relevant evidence early next year.

Meanwhile, the first signs of legal action over the withdrawal of rofecoxib (Vioxx) have emerged, with solicitors warning UK cases were currently being compiled and their validity checked.

David Harris, an expert in product and pharmaceutical liability law at solicitors Alexander Harris, said the firm had received more than 50 calls from patients who claimed to have had strokes and serious cardiac events.

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say